De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Aspen Pharmacare Holdings Beheer
Beheer criteriumcontroles 4/4
De CEO Aspen Pharmacare Holdings' is Stephen Saad, benoemd in Jan2000, heeft een ambtstermijn van 24.75 jaar. De totale jaarlijkse vergoeding van { bedraagt ZAR 24.15M, bestaande uit 38% salaris en 62% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 12.84% van de aandelen van het bedrijf, ter waarde ZAR 11.14B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.6 jaar en 5.5 jaar.
Belangrijke informatie
Stephen Saad
Algemeen directeur
R24.1m
Totale compensatie
| Percentage CEO-salaris | 38.0% |
| Dienstverband CEO | 24.8yrs |
| Eigendom CEO | 12.9% |
| Management gemiddelde ambtstermijn | 7.6yrs |
| Gemiddelde ambtstermijn bestuur | 5.5yrs |
Recente managementupdates
Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01
Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02Recent updates
Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden
Oct 01Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59
Sep 10We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt
May 08Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable
Mar 05Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Dec 22Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | R4b |
| Mar 31 2024 | n/a | n/a | R5b |
| Dec 31 2023 | n/a | n/a | R5b |
| Sep 30 2023 | n/a | n/a | R5b |
| Jun 30 2023 | R24m | R9m | R5b |
| Mar 31 2023 | n/a | n/a | R6b |
| Dec 31 2022 | n/a | n/a | R6b |
| Sep 30 2022 | n/a | n/a | R6b |
| Jun 30 2022 | R23m | R9m | R6b |
| Mar 31 2022 | n/a | n/a | R6b |
| Dec 31 2021 | n/a | n/a | R6b |
| Sep 30 2021 | n/a | n/a | R5b |
| Jun 30 2021 | R24m | R8m | R5b |
| Mar 31 2021 | n/a | n/a | R4b |
| Dec 31 2020 | n/a | n/a | R4b |
| Sep 30 2020 | n/a | n/a | R4b |
| Jun 30 2020 | R23m | R8m | R3b |
| Mar 31 2020 | n/a | n/a | R3b |
| Dec 31 2019 | n/a | n/a | R870m |
| Sep 30 2019 | n/a | n/a | R1b |
| Jun 30 2019 | R14m | R8m | R2b |
| Mar 31 2019 | n/a | n/a | R3b |
| Dec 31 2018 | n/a | n/a | R5b |
| Sep 30 2018 | n/a | n/a | R5b |
| Jun 30 2018 | R17m | R7m | R6b |
Compensatie versus markt: De totale vergoeding ($USD 1.38M ) Stephen } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de ZA markt ($USD 2.04M ).
Compensatie versus inkomsten: De vergoeding van Stephen is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Stephen Saad (60 yo)
24.8yrs
Tenure
R24,149,000
Compensatie
Mr. Stephen Bradley Saad, BCom, CA(SA), serves as the Group Chief Executive Officer of Aspen Pharmacare Canada Inc. Mr. Stephen has been the Group Chief Executive Officer of Aspen Pharmacare Holdings Limit...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Group CEO & Executive Director | 24.8yrs | R24.15m | 12.86% ZAR 11.0b | |
| Group CFO & Executive Director | 25.8yrs | R15.55m | geen gegevens | |
| Group Chief Operations Officer & Responsible Pharmacist | 10.9yrs | R16.59m | geen gegevens | |
| Group Chief Advisor | 2.8yrs | R12.62m | 4.32% ZAR 3.7b | |
| Group Chief Corporate Services Officer & Executive Director | less than a year | R14.21m | geen gegevens | |
| Group Chief Strategic Development Officer | 4.4yrs | R13.87m | geen gegevens | |
| Investor Relations Manager | no data | geen gegevens | geen gegevens | |
| Regional Chief Executive Officer of Asia Pacific | 10.8yrs | geen gegevens | geen gegevens | |
| Chief Executive Officer of Aspen Global Incorporated | 7.6yrs | geen gegevens | geen gegevens | |
| Group Company Secretary | less than a year | geen gegevens | geen gegevens | |
| Corporate Affairs & Investor Relations Executive | no data | geen gegevens | geen gegevens |
7.6yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van APN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Group CEO & Executive Director | 25.8yrs | R24.15m | 12.86% ZAR 11.0b | |
| Group CFO & Executive Director | 2.8yrs | R15.55m | geen gegevens | |
| Group Chief Corporate Services Officer & Executive Director | less than a year | R14.21m | geen gegevens | |
| Lead Independent Non-Executive Director | 5.5yrs | R932.00k | geen gegevens | |
| Non-Executive Director | 25.8yrs | R465.00k | geen gegevens | |
| Independent Non-Executive Chairman | 12.5yrs | R1.41m | geen gegevens | |
| Independent Non-Executive Director | 2.8yrs | R548.00k | geen gegevens | |
| Non-Executive Director | 9.7yrs | R364.00k | geen gegevens | |
| Independent Non-Executive Director | 6.3yrs | R958.00k | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 5.5yrs | R448.00k | geen gegevens |
5.5yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van APN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).